InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial
26 juin 2023 08h00 HE
|
InspireMD, Inc.
Trial designed to support potential U.S. marketing approval of the CGuard™ Prime EPS stent system Study also included first-in-human cases treated with CGuard Prime CAS stent delivery platform ...
InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
18 mai 2023 08h00 HE
|
InspireMD, Inc.
TEL AVIV, Israel and MIAMI, May 18, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today...
InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update
16 mai 2023 07h00 HE
|
InspireMD, Inc.
- Completed transformational private placement for up to $113.6 million, including $42.2 million upfront - - Generated Q1 2023 CGuard EPS revenue of $1.2 million, an increase of 6.7% over...
InspireMD Announces Private Placement of Up to $113.6 Million
15 mai 2023 08h00 HE
|
InspireMD, Inc.
Led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members $42.2 million financing upfront with up to an additional $71.4...
InspireMD Announces May 16, 2023 as New Date for First Quarter 2023 Results Conference Call and Webcast
12 mai 2023 16h05 HE
|
InspireMD, Inc.
- Conference call and webcast to be held at 8:30 a.m. EDT - TEL AVIV, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent...
InspireMD Announces May 15th as New Date for First Quarter 2023 Financial Results and Corporate Business Update
05 mai 2023 08h00 HE
|
InspireMD, Inc.
-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, May 05, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent...
InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform
01 mai 2023 08h00 HE
|
InspireMD, Inc.
Procedure performed as part of the company’s ongoing CGuardians U.S. Investigational Device Exemption (IDE) trial designed to support potential U.S. marketing approval of the CGuard stent system ...
InspireMD to Report First Quarter 2023 Financial Results on May 9, 2023, and Provide Corporate Business Update
27 avr. 2023 08h00 HE
|
InspireMD, Inc.
TEL AVIV, Israel, April 27, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease...
InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
30 mars 2023 07h00 HE
|
InspireMD, Inc.
- 2022 CGuard EPS revenue of $5.1 million increased 18.9% over 2021 - - Resumed shipments of CGuard EPS to CE Mark territories under the pre-existing Medical Device Directive (MDD)...
InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer
20 mars 2023 08h00 HE
|
InspireMD, Inc.
TEL AVIV, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that...